Literature DB >> 24288047

Gender differences in Iranian patients with ankylosing spondylitis.

Abtin Shahlaee1, Mahdi Mahmoudi, Mohammad Hossein Nicknam, Elham Farhadi, Sasan Fallahi, Ahmad Reza Jamshidi.   

Abstract

Inequalities in features and severity of ankylosing spondylitis (AS) have been noticed between men and women, suggesting a possible influence of gender on disease phenotypes. Comparing disease features and characterization of gender differences in clinical features and medications could help elucidate the potential influence of gender on the severity of AS in patients. This study aims to assess the influence of gender on disease patterns in Iranian patients with AS. Three hundred and twenty patients diagnosed with primary AS were assessed for demographic variables, clinical manifestations, HLA status, disease severity, functional capacities, quality of life, and treatment status. Sixty-seven women and 253 men were included corresponding to a male to female ratio of 3.78:1. Both groups were similar regarding ethnicity, positive family history, and juvenile onset AS. HLA-B27 was more frequent among males (78.3 vs. 55.2%; p < 0.001). There was a higher proportion of female patients with overall enthesitis (p < 0.05). Extra-articular manifestations and treatment modalities presented similar frequencies in both genders. No difference in gender-associated diagnostic delays was observed. Female disease was at least as severe as male disease, and in some aspects, females presented with more severe disease. Despite a relatively similar disease profile, we observed a higher rate of enthesitis among women. Together with the equally high rate of disease activity indices in both genders, these findings indicate an overall longer delay to diagnosis in our country. Early detection and specialized care would be of great practical importance.

Entities:  

Mesh:

Year:  2013        PMID: 24288047     DOI: 10.1007/s10067-013-2439-4

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  33 in total

Review 1.  Women with ankylosing spondylitis: a review.

Authors:  Wonuk Lee; John D Reveille; Michael H Weisman
Journal:  Arthritis Rheum       Date:  2008-03-15

2.  Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis.

Authors:  L C Doward; A Spoorenberg; S A Cook; D Whalley; P S Helliwell; L J Kay; S P McKenna; A Tennant; D van der Heijde; M A Chamberlain
Journal:  Ann Rheum Dis       Date:  2003-01       Impact factor: 19.103

3.  The Bath Ankylosing Spondylitis Patient Global Score (BAS-G).

Authors:  S D Jones; A Steiner; S L Garrett; A Calin
Journal:  Br J Rheumatol       Date:  1996-01

4.  Evaluation of the Iranian versions of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), the Bath Ankylosing Spondylitis Functional Index (BASFI) and the Patient Acceptable Symptom State (PASS) in patients with ankylosing spondylitis.

Authors:  Katayoon Bidad; Sasan Fallahi; Mahdi Mahmoudi; Ahmadreza Jamshidi; Elham Farhadi; Alipasha Meysamie; Mohammad Hossein Nicknam
Journal:  Rheumatol Int       Date:  2011-11-20       Impact factor: 2.631

Review 5.  Are there gender differences in severity of ankylosing spondylitis? Results from the PSOAS cohort.

Authors:  Wonuk Lee; John D Reveille; John C Davis; Thomas J Learch; Michael M Ward; Michael H Weisman
Journal:  Ann Rheum Dis       Date:  2006-11-24       Impact factor: 19.103

6.  Prevalence of the spondyloarthritides in patients with uveitis.

Authors:  Roland Linder; Axel Hoffmann; Richard Brunner
Journal:  J Rheumatol       Date:  2004-11       Impact factor: 4.666

7.  A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index.

Authors:  A Calin; S Garrett; H Whitelock; L G Kennedy; J O'Hea; P Mallorie; T Jenkinson
Journal:  J Rheumatol       Date:  1994-12       Impact factor: 4.666

Review 8.  Clinical features and associated systemic diseases of HLA-B27 uveitis.

Authors:  M L Tay-Kearney; B L Schwam; C Lowder; J P Dunn; D M Meisler; S Vitale; D A Jabs
Journal:  Am J Ophthalmol       Date:  1996-01       Impact factor: 5.258

Review 9.  Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Global Score (BAS-G), Bath Ankylosing Spondylitis Metrology Index (BASMI), Dougados Functional Index (DFI), and Health Assessment Questionnaire for the Spondylarthropathies (HAQ-S).

Authors:  Jane Zochling
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-11       Impact factor: 4.794

10.  The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people.

Authors:  Fausto Salaffi; Marina Carotti; Stefania Gasparini; Michele Intorcia; Walter Grassi
Journal:  Health Qual Life Outcomes       Date:  2009-03-18       Impact factor: 3.186

View more
  10 in total

1.  Promoter hypermethylation of BCL11B gene correlates with downregulation of gene transcription in ankylosing spondylitis patients.

Authors:  J Karami; M Mahmoudi; A Amirzargar; M Gharshasbi; A Jamshidi; S Aslani; M H Nicknam
Journal:  Genes Immun       Date:  2017-08-10       Impact factor: 2.676

2.  The disease burden of axial spondyloarthritis: through a gendered lens.

Authors:  Sara Khan; Divya Shridharmurthy; Kate L Lapane; Catherine Dube; Jonathan Kay; Esther Yi; Shao-Hsien Liu
Journal:  Clin Rheumatol       Date:  2022-01-06       Impact factor: 2.980

Review 3.  Sexual dimorphism in the prevalence, manifestation and outcomes of axial spondyloarthritis.

Authors:  Rachael Stovall; Irene E van der Horst-Bruinsma; Shao-Hsien Liu; Tamara Rusman; Lianne S Gensler
Journal:  Nat Rev Rheumatol       Date:  2022-09-15       Impact factor: 32.286

4.  Impact of gender, work, and clinical presentation on diagnostic delay in Italian patients with primary ankylosing spondylitis.

Authors:  F Bandinelli; G Salvadorini; A Delle Sedie; L Riente; S Bombardieri; M Matucci-Cerinic
Journal:  Clin Rheumatol       Date:  2015-08-04       Impact factor: 2.980

5.  The Importance of Sex Stratification in Autoimmune Disease Biomarker Research: A Systematic Review.

Authors:  Kristy Purnamawati; Jamie Ann-Hui Ong; Siddharth Deshpande; Warren Kok-Yong Tan; Nihar Masurkar; Jackson Kwee Low; Chester Lee Drum
Journal:  Front Immunol       Date:  2018-06-04       Impact factor: 7.561

Review 6.  Gender Differences in Axial Spondyloarthritis: Women Are Not So Lucky.

Authors:  T Rusman; R F van Vollenhoven; I E van der Horst-Bruinsma
Journal:  Curr Rheumatol Rep       Date:  2018-05-12       Impact factor: 4.592

7.  Association between rs6759298 and Ankylosing Spondylitis in Iranian Population.

Authors:  Mahdi Mahmoudi; Masoud Garshasbi; Amir Ashraf-Ganjouei; Ali Javinani; Mahdi Vojdanian; Masoumeh Saafi; Nooshin Ahmadzadeh; Ahmadreza Jamshidi
Journal:  Avicenna J Med Biotechnol       Date:  2018 Jul-Sep

8.  Low BASDAI score alone is not a good predictor of anti-tumor necrosis factor treatment efficacy in ankylosing spondylitis: a retrospective cohort study.

Authors:  Bora Nam; Bon San Koo; Tae-Han Lee; Ji-Hui Shin; Jin-Ju Kim; Seunghun Lee; Kyung Bin Joo; Tae-Hwan Kim
Journal:  BMC Musculoskelet Disord       Date:  2021-02-04       Impact factor: 2.362

9.  Gender Differences in Ankylosing Spondylitis Patients with Advanced Hip Involvement: Results from A Matched Retrospective Cohort Study.

Authors:  Liang-Liang Li; Jun Fu; Chi Xu; Ming Ni; Wei Chai; Li-Bo Hao; Yong-Gang Zhou; Ji-Ying Chen
Journal:  Orthop Surg       Date:  2021-12-13       Impact factor: 2.071

10.  Sex and gender differences in axial spondyloarthritis: myths and truths.

Authors:  Tamara Rusman; Rianne E van Bentum; Irene E van der Horst-Bruinsma
Journal:  Rheumatology (Oxford)       Date:  2020-10-01       Impact factor: 7.580

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.